Humacyte, Inc.
Humacyte, Inc. (HUMA) Financial Performance & Income Statement Overview
View comprehensive annual and quarterly summaries for Humacyte, Inc. (HUMA), featuring income statements, balance sheets, and cash flow data.
Humacyte, Inc. (HUMA) Income Statement & Financial Overview
Review Humacyte, Inc. HUMA income statement with detailed quarterly and annual figures.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $7.23M | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $3.61M | $0.00 | $1.82M | $1.79M |
| Gross Profit | $3.61M | $0.00 | -$1.82M | -$1.79M |
| Gross Profit Ratio | $0.50 | $0.00 | ||
| R&D Expenses | $20.66M | $22.93M | $23.75M | $21.26M |
| SG&A Expenses | $11.05M | $7.31M | $3.92M | $3.52M |
| Operating Expenses | $31.70M | $30.23M | $27.68M | $24.79M |
| Total Costs & Expenses | $35.32M | $30.23M | $29.50M | $26.58M |
| Interest Income | $852000.00 | $911000.00 | $1.31M | $1.03M |
| Interest Expense | $2.51M | $2.44M | $2.52M | $1.82M |
| Depreciation & Amortization | $1.81M | $1.81M | $1.82M | $1.79M |
| EBITDA | -$16.62M | -$30.23M | -$52.33M | -$28.29M |
| EBITDA Ratio | -$2.30 | |||
| Operating Income | -$28.09M | -$30.23M | -$29.50M | -$26.58M |
| Operating Income Ratio | -$3.89 | |||
| Other Income/Expenses (Net) | $7.15M | -$8.97M | -$27.16M | -$5.32M |
| Income Before Tax | -$20.94M | -$39.20M | -$56.66M | -$31.90M |
| Income Before Tax Ratio | -$2.90 | |||
| Income Tax Expense | $0.00 | $0.00 | $0.00 | $1.75M |
| Net Income | -$20.94M | -$39.20M | -$56.66M | -$31.90M |
| Net Income Ratio | -$2.90 | |||
| EPS | $1.08 | -$0.33 | -$0.48 | -$0.29 |
| Diluted EPS | $1.08 | -$0.33 | -$0.48 | -$0.29 |
| Weighted Avg Shares Outstanding | $118.48M | $119.41M | $119.17M | $108.25M |
| Weighted Avg Shares Outstanding (Diluted) | $118.48M | $119.41M | $119.17M | $108.25M |
Over the past four quarters, Humacyte, Inc. demonstrated steady revenue growth, increasing from $0.00 in Q1 2024 to $7.23M in Q4 2024. Operating income reached -$28.09M in Q4 2024, maintaining a consistent -389% margin over recent quarters. Despite fluctuations in R&D and SG&A expenses, EBITDA remained robust at -$16.62M, reflecting operational efficiency. Net income rose to -$20.94M, with EPS at $1.08. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan